Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRP for Facetogenic Low Back Pain
NCT05250947Phase 1Terminated
- Start
- Jan 2023
- Primary completion
- May 2024
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous platelet-rich plasma in lumbar spondylosis. Primary endpoints: Number of adverse device effects at Day 0 and Number of suspected acute adverse reactions to the treatment. Started Jan 2023; status: terminated.
02
Drugs
autologous platelet-rich plasma
03
Conditions
lumbar spondylosis
Beyond the preview
Go deeper on NCT05250947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05250947.